FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 PET Positivity After Two Cycles of ABVD Is Associated with a... November 22, 2023 Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval November 30, 2020 Load more HOT NEWS ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk... Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... Coronavirus reports – Part 8: “Going into hospital during this time... Merging the Histologic and Molecular Data Into an Integrated Score Significantly...
